GV, Mass General Brigham Ventures and Lonza helped Affinia Therapeutics raise $110m to commercialise work originating at Harvard.

Affinia Therapeutics, a US-based gene therapy developer based on research at Harvard Medical School, completed a $110m series B round on Monday featuring chemicals producer Lonza, internet and technology group Alphabet and healthcare provider Mass General Brigham.
EcoR1 Capital and Farallon Capital Management co-led the round, which included investment and financial services group Fidelity’s F-Prime Capital subsidiary, while Alphabet and Mass General Brigham took part through GV and Mass General Brigham Ventures respectively.
Avidity Partners, Casdin Capital, Octagon…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?